InsidersTradesSigma
Total declarations
Companies
▲ Purchases (14 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
14
Disclosed sells
1
T+90 hit rate
58%
T+90 mean return
+9.4%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Foehr Matthew W, Président. Officer active across 5 companies, notably Ligand Pharmaceuticals INC. Aggregated, 50 filings have been published. Breakdown: 14 buys · 1 sell. Total volume traded: €7.7m. Activity tracked since 28 May 2021. The latest transaction was disclosed on 7 April 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Foehr Matthew W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations50 total
36,459 shares0Common StockSEC:0001628280-26-024136:0
19,244 shares@ US$1.490.3% of flowCommon StockSEC:0001628280-26-024136:1
58,333 sharesCommon StockSEC:0001237556-26-000001:0
36,458 shares0Common StockSEC:0001628280-26-008709:0
16,000 shares@ US$3.3311.6% of flowCommon Stock, par value $0.00001 per shareSEC:0001193125-26-003109:0
26,554 shares0Common StockSEC:0001237556-25-000013:0
540,540 shares@ US$1.859.8% of flowCommon StockSEC:0001237556-25-000009:0
20,786 shares@ US$8.0033.5% of flowCommon Stock, par value $0.00001 per shareSEC:0000950170-25-053867:0
36,458 shares0Common StockSEC:0001628280-25-016993:0
26,549 sharesCommon StockSEC:0001846253-25-000013:0
77,003 shares0Common StockSEC:0001846253-25-000004:0
26,555 sharesCommon StockSEC:0001846253-24-000097:0
31,074 shares@ US$3.681.4% of flowCommon StockSEC:0001846253-24-000090:0
18,644 shares@ US$3.680.8% of flowCommon StockSEC:0001846253-24-000058:0
240,000 shares@ US$4.41612.5% of flowCommon StockSEC:0001846253-24-000036:0
Canonical exit: 22 Aug 2024 (T+90)
1,431,618 sharesCommon StockSEC:0001846253-24-000014:0
36,458 sharesCommon StockSEC:0002001011-24-000045:0
93,222 shares@ US$3.684.0% of flowCommon StockSEC:0002001011-24-000037:0
225,000 shares@ US$5.1913.7% of flowCommon StockSEC:0002001011-24-000033:0
Canonical exit: 20 Jun 2024 (T+90)
10,770 sharesCommon StockSEC:0002001011-24-000021:0
33,173 sharesCommon StockSEC:0002001011-24-000005:0
200,000 shares@ US$5.0511.9% of flowCommon StockSEC:0002001011-23-000015:0
Canonical exit: 11 Mar 2024 (T+90)
26,556 sharesCommon StockSEC:0002001011-23-000009:0
95,000 shares@ US$4.26864.8% of flowCommon StockSEC:0000950170-23-062463:0
Canonical exit: 8 Feb 2024 (T+90)
45,000 shares@ US$5.482.9% of flowCommon StockSEC:0001846253-23-000099:0
Canonical exit: 12 Nov 2023 (T+90)
25 of 50 declarations
About Foehr Matthew W
Matthew W. Foehr is Président. He has 50 filings in total, and in the sample of recent filings covering the period from 2016-01-11 to 2026-04-07, buy amounts are EUR 7646221 and sell amounts are EUR 24535, with a modal transaction nature of Levée d'options. He is associated with OmniAb, Inc., Ligand Pharmaceuticals INC, Viking Therapeutics, Inc., OmniAb Operations, Inc. and RITTER PHARMACEUTICALS INC.
